Introduction
In the genetic diagnosis of Stargardt disease (STGD), a frustrating "diagnostic gap" exists, with 30-40% of cases remaining unsolved after standard exome sequencing (ES). This strongly points to non-coding regions, particularly deep intronic variants (DIVs). A recent study on a Chinese STGD cohort clearly demonstrates the pivotal role of the RDDC RNA Splicer tool in closing this gap: an astonishing 45% (18 of 40) of the WES-unsolved families in the study were confirmed to be caused by DIVs, and RDDC's precise predictions were the core bridge linking variant discovery to functional validation.
The Research Challenge: From WGS Discovery to Functional Proof
The study performed Genomic Sequencing (GS) or enhanced ES on 40 WES-unsolved STGD families to hunt for pathogenic non-coding variants. The team successfully identified seven different DIVs in the ABCA4 gene across 18 families.
However, finding a variant is not enough. The greatest challenge is proving its pathogenicity. Researchers must determine exactly how these non-coding changes impact the mRNA splicing process, which requires a reliable in silico tool to guide subsequent experiments.
RDDC's Precise Prediction: Providing Testable Splicing Patterns
The research team utilized the RDDC RNA Splicer tool to predict the splicing effects of all seven DIVs. The RDDC analysis was definitive: it predicted that all DIVs would lead to pseudoexon insertion or intron retention.
The value of RDDC was not just its "yes/no" conclusion, but its specific, verifiable mechanistic hypotheses. For example, for the most common DIV allele, c.161-395G>A, RDDC predicted multiple complex aberrant splicing patterns, including pseudoexon insertions of different sizes (PE1b, PE1c, PE1d). This provided the critical theoretical basis and clear targets for the minigene assays.
Perfect Validation by Minigene Assay
Based on RDDC's predictions, the team performed in vitro functional validation on four of the DIVs. The experimental results were highly consistent with the RDDC predictions: all tested DIVs were confirmed to cause aberrant splicing, with the proportion of incorrectly spliced mRNA exceeding 50% in all cases.
This perfect closed loop—from in silico prediction to in vitro validation—confirmed the pathogenicity of these DIVs. This case powerfully demonstrates that RDDC RNA Splicer is a robust tool for researchers facing WES-negative cases. It accurately predicts the functional consequences of deep intronic variants, successfully linking genotype to phenotype. This not only provided a diagnosis for nearly half of the unsolved STGD cases but also identified new targets for future splice-regulating therapies, such as antisense oligonucleotides (ASOs).
Content Source and Disclaimer
This article is a compilation and interpretation of the scientific study cited below, intended to highlight the application of RDDC bioinformatics tools. All research data and conclusions belong to the original authors and publication.
Original Article:
Sun W, Liu Y, Zhang Y, et al. ABCA4 Deep Intronic Variants Contributed to Nearly Half of Unsolved Stargardt Cases With a Milder Phenotype. Investigative Ophthalmology & Visual Science. 2024 Mar 1;65(3):18.
Article Link: https://pubmed.ncbi.nlm.nih.gov/39883546/
